Buy now (pre-market ~51.63): price is in a bullish uptrend with positive momentum, and Street targets imply sizable upside.
Near-term setup is momentum-friendly (bullish MAs + expanding positive MACD), despite being close to resistance.
Sentiment is mixed: options positioning is put-heavy (defensive/bearish hedging) and insiders have been selling, but analysts have recently turned materially more constructive.
Pattern-based forward odds (given): ~+3.99% next month bias (shorter horizons close to flat).
Options Data
Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning/Sentiment: Put-heavy open interest (OI P/C 6.97) and put-heavy volume (Vol P/C 2.97) suggests traders are net defensive / hedging, not aggressively chasing calls.
Activity: Today’s option volume vs 30D average is elevated (18.25x), implying heightened attention/positioning.
Volatility: IV30 87.23 vs HV 66.18 (options pricing in larger-than-recent realized moves). IV percentile 22.8 / IV rank 12.54 (IV not extreme vs its own history).
Technical Summary
Sell
1
Buy
11
Positive Catalysts
supports a stronger fundamental narrative.
Neutral/Negative Catalysts
Insiders are selling (selling amount up 189.75% over the last month), which can cap near-term upside.
Options market skew is bearish/defensive (very high put/call ratios).
Prior clinical/program disappointment lingers in sentiment: rosnilimab UC miss/discontinuation previously drove target cuts (still part of the overhang).
No recent supportive news this week; the stock may need technical momentum or the next catalyst to keep pushing through resistance.
Net income: $15.11M, -146.00% YoY (sharp decline vs prior year’s comparison).
EPS: $0.52, -145.61% YoY.
Gross margin: 100% (stable; typical for milestone/royalty-like revenue mixes).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: After multiple cuts in Nov–Dec 2025 (post-UC trial disappointment), ratings/targets re-accelerated upward into Dec 2025–Jan 2026 on ANB033 Phase 1 / pipeline conviction.
Wall Street pros: Clear upside framing around ANB033 and pipeline optionality; multiple Buys/Overweights with materially higher targets.
Wall Street cons: History of program setbacks (rosnilimab UC miss) and model resets show the story remains catalyst-driven and sensitive to clinical readouts.
Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 71.33 USD with a low forecast of 50 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 71.33 USD with a low forecast of 50 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.900
Low
50
Averages
71.33
High
140
Current: 47.900
Low
50
Averages
71.33
High
140
Barclays
Etzer Darout
Overweight
maintain
$55 -> $78
AI Analysis
2026-01-20
Reason
Barclays
Etzer Darout
Price Target
$55 -> $78
AI Analysis
2026-01-20
maintain
Overweight
Reason
Barclays analyst Etzer Darout raised the firm's price target on AnaptysBio to $78 from $55 and keeps an Overweight rating on the shares. The firm cites increased conviction in ANB033 for the target boost.
UBS
Neutral -> Buy
upgrade
$20 -> $70
2026-01-07
Reason
UBS
Price Target
$20 -> $70
2026-01-07
upgrade
Neutral -> Buy
Reason
UBS upgraded AnaptysBio (ANAB) to Buy from Neutral with a price target of $70, up from $20, as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANAB
